Notable concerns that warrant closer review
Management acknowledges significant pricing pressures and increased rebate demands in the US market, impacting net prices despite underlying demand.. The company is strategically investing in R&D and made a key acquisition (Akero Therapeutics) to bolster its focus on obesity, diabetes, and related conditions like MASH.. The company faces significant risks related to cybersecurity and data breaches, which could lead to substantial financial and reputational damage.. US pricing pressure and declining net prices due to increased rebates.